Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Administration of rivoceranib is continued until disease progression, occurrence···【more】
Release date：2026-01-28Recommended：171
The recommended dosage of Revuforj varies according to the patient's body we···【more】
Release date：2026-01-28Recommended：137
Take Revuforj exactly as directed by your healthcare provider. Do not change you···【more】
Release date：2026-01-28Recommended：160
Your doctor may prescribe Revuforj tablets in multiple dosage strengths, and it ···【more】
Release date：2026-01-28Recommended：121
Revumenib is a menin inhibitor that blocks the interaction between wild-type lys···【more】
Release date：2026-01-28Recommended：128
Revuforj tablets are available in different dosage strengths, each corresponding···【more】
Release date：2026-01-28Recommended：170
Revuforj is typically indicated for the treatment of patients with specific type···【more】
Release date：2026-01-28Recommended：161
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug A···【more】
Release date：2026-01-28Recommended：151
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from ···【more】
Release date：2026-01-28Recommended：142
Recently, Syndax Pharmaceuticals announced additional positive data from the AUG···【more】
Release date：2026-01-28Recommended：134
Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor, primarily i···【more】
Release date：2026-01-27Recommended：158
Lorlatinib is a third-generation targeted therapy indicated for ALK-positive met···【more】
Release date：2026-01-26Recommended：126
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
